Quantbot Technologies LP Invests $3.96 Million in Cencora, Inc. $COR

Quantbot Technologies LP acquired a new stake in shares of Cencora, Inc. (NYSE:COR) during the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 13,985 shares of the company’s stock, valued at approximately $3,957,000.

A number of other large investors also recently bought and sold shares of COR. Kemnay Advisory Services Inc. purchased a new stake in Cencora during the fourth quarter worth $25,000. Oakworth Capital Inc. purchased a new position in shares of Cencora in the 4th quarter valued at $26,000. Elyxium Wealth LLC bought a new position in shares of Cencora in the 4th quarter worth $27,000. Elevation Wealth Partners LLC lifted its stake in shares of Cencora by 506.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 97 shares of the company’s stock worth $27,000 after purchasing an additional 81 shares during the last quarter. Finally, Archer Investment Corp lifted its stake in shares of Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In related news, Director Lauren M. Tyler acquired 550 shares of the stock in a transaction dated Monday, June 22nd. The stock was acquired at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the purchase, the director owned 4,359 shares of the company’s stock, valued at approximately $1,177,932.57. This represents a 14.44% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.38% of the company’s stock.

Cencora Price Performance

Shares of COR stock opened at $317.89 on Monday. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.58 and a current ratio of 0.93. The firm has a market capitalization of $60.66 billion, a price-to-earnings ratio of 23.62, a PEG ratio of 1.83 and a beta of 0.57. The stock’s 50-day simple moving average is $302.59 and its 200-day simple moving average is $311.52.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $4.48 EPS for the quarter, beating the consensus estimate of $4.35 by $0.13. The firm had revenue of $84.75 billion during the quarter, compared to analyst estimates of $84.31 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. Cencora’s revenue was up 5.1% on a year-over-year basis. During the same period last year, the firm posted $4.00 EPS. As a group, equities analysts forecast that Cencora, Inc. will post 17.87 earnings per share for the current fiscal year.

Cencora announced that its Board of Directors has approved a share buyback program on Thursday, May 21st that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to reacquire up to 3.9% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its stock is undervalued.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Friday, August 14th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. Cencora’s dividend payout ratio (DPR) is currently 17.83%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on COR shares. Royal Bank Of Canada started coverage on shares of Cencora in a report on Wednesday. They issued a “sector perform” rating and a $330.00 price target on the stock. Robert W. Baird set a $370.00 price objective on shares of Cencora in a research note on Thursday, August 6th. Morgan Stanley increased their target price on shares of Cencora from $342.00 to $346.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Wall Street Zen upgraded shares of Cencora from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Barclays reduced their price target on Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 10th. Thirteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $370.85.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.